84. サルコイドーシス [臨床試験数:143,薬物数:221(DrugBank:79),標的遺伝子数:82,標的パスウェイ数:165

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004148-31-NL
(EUCTR)
26/02/202015/11/2019The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trialThe PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial - PREDMETH trial pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Methotrexate
Product Name: methotrexate
INN or Proposed INN: methotrexate
Other descriptive name: METHOTREXATE
Trade Name: Prednison
Product Name: Prednison
INN or Proposed INN: prednisone
Other descriptive name: PREDNISONE
Erasmus Medisch Centrum Dept. of PulmonologyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
132Phase 4Netherlands
2NCT03593759
(ClinicalTrials.gov)
January 15, 201927/6/2018Cardiac Sarcoidosis Randomized TrialCardiac Sarcoidosis Multi-Center Randomized Controlled TrialCardiac Sarcoidosis;SarcoidosisDrug: Prednisone;Drug: MethotrexateOttawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR)Recruiting18 YearsN/AAll194Phase 3United States;Canada;United Kingdom
3NCT01210677
(ClinicalTrials.gov)
April 201427/9/2010Cardiac Sarcoidosis Response To Steroids TrialCArdiac Sarcoidosis Response TO steRoids (CASTOR) TrialCardiac Sarcoidosis;SarcoidosisDrug: PrednisoneOttawa Heart Institute Research CorporationNULLWithdrawn18 YearsN/ABoth0Phase 4Canada
4NCT02200146
(ClinicalTrials.gov)
March 200910/7/2014Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.Pulmonary SarcoidosisDrug: Prednisone;Drug: Hydroxychloroquine + PrednisoneUniversity of Milano BicoccaAgenzia Italiana del FarmacoCompleted18 Years70 YearsBoth94Phase 3Italy
5EUCTR2008-001340-39-IT
(EUCTR)
30/06/200813/06/2008Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSASHydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS Pulmonary SarcoidosisTrade Name: PLAQUENIL*25CPR RIV 200MG
INN or Proposed INN: Hydroxychloroquine
Trade Name: DELTACORTENE*10CPR 25MG
INN or Proposed INN: Prednisone
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00000596
(ClinicalTrials.gov)
June 197827/10/1999Diffuse Fibrotic Lung DiseaseLung Diseases;Pulmonary Fibrosis;SarcoidosisDrug: prednisone;Drug: cyclophosphamide;Drug: dapsoneNational Heart, Lung, and Blood Institute (NHLBI)NULLCompleted18 YearsN/ABothPhase 2NULL